U.S., Oct. 15 -- ClinicalTrials.gov registry received information related to the study (NCT07215962) titled 'Long-Term Safety Outcomes and First-Line Treatment Patterns in Patients With Non-Small Cell Lung Cancer and Programmed Death-1 (Pd-L1) <1%' on Oct. 09.
Brief Summary: The purpose of this study is to assess the treatment-related adverse events and associated healthcare resource use in programmed death ligand 1 (PD-L1) negative individuals diagnosed with advanced/metastatic non-small cell lung cancer (NSCLC) who received first-line therapy
Study Start Date: Nov. 22, 2024
Study Type: OBSERVATIONAL
Condition:
Non-small Cell Lung Cancer (NSCLC)
Intervention:
BIOLOGICAL: Nivolumab + ipilimumab
According to the product label
BIOLOG...